关键词:
glycemia
liver
fluvoxamine
摘要:
Whether hyperinsulinemia is required for stimulation of net hepatic glucose uptake (NHGU) by a selective serotonin reuptake inhibitor (SSRI) was examined in four groups of conscious 42-h-fasted dogs, using arteriovenous difference and tracer ([3-H-3] glucose) techniques. Experiments consisted of equilibration (-120 to -30 min), basal (-30 to 0 min), and experimental periods (Exp;0-240 min). During Exp, somatostatin, intraportal insulin [at basal (Ins groups) or 4-fold basal rates (INS groups)], basal intraportal glucagon, and peripheral glucose (to double hepatic glucose load) were infused. In the Fluv-Ins (n=7) and Fluv-INS groups (n=6), saline was infused intraportally from 0 to 90 min (P1), and fluvoxamine was infused intraportally at 2 ***(-1).min(-1) from 90 to 240 min (P2). Sal-Ins (n=9) and Sal-INS (n=8) received intraportal saline in P1 and P2. NHGU during P2 was 8.4+/-1.4 and 6.9+/-2.3 ***(-1).min(-1) in Sal-Ins and Fluv-Ins, respectively (not significant), and 13.3+/-2.2 and 20.9+/-3.1 ***(-1).min(-1) (P<0.05) in Sal-INS and Fluv-INS. Unidirectional (tracer-determined) hepatic glucose uptake was twofold greater (P<0.05) in Fluv-INS than Sal-INS. Net hepatic carbon retention during P2 was significantly greater in Fluv-INS than Sal-INS (18.5+/-2.7 vs. 12.2+/-1.9 ***(-1).min(-1)). Nonhepatic glucose uptake was reduced in Fluv-INS vs. Sal-INS (20.0+/-1.3 vs. 38.4+/-5.4 ***(-1).min(-1), P<0.05). Intraportal fluvoxamine enhanced NHGU and net hepatic carbon retention in the presence of hyperinsulinemia but not euinsulinemia, suggesting that hepatocyte-targeted SSRIs may reduce postprandial hyperglycemia.